Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The United Arab Emirates (UAE), the Kingdom of Bahrain, Kuwait, Oman, and Qatar have authorised sotrovimab for emergency use. Local experience among physicians include recent successful COVID-19 vaccine pivotal studies supported by the authorities' willingness to expedite understanding of the role of monoclonal antibodies such as sotrovimab in the management of COVID-19 and expertise to integrate the latest knowledge into the local or regional COVID-19 management guidelines. The aim of this study is to collect local clinical evidence for sotrovimab effect in the real-life setting in the UAE and the Kingdom of Bahrain. Overall study population is 20,000 and the duration of the study will be approximately six months from recruitment date.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sotrovimab Arm |
| ||
| Control |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sotrovimab | Drug | collect local clinical evidence for sotrovimab effect in the real-life setting |
|
| Measure | Description | Time Frame |
|---|---|---|
| • Proportion of patients with COVID-19 progression through Day 29 after sotrovimab administration: |
| 6 months |
| To assess the impact of sotrovimab on the strength and duration of the immune response to natural SARS-CoV-2 infection in real-life setting in the UAE and Bahrain. | Defined as • Change from baseline in mean levels of elevated SARS-CoV-2 functional neutralising antibodies at Day 29, Day 60 and Day 180 after sotrovimab administration, these will be presented as proportion of patients with that response | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the impact of sotrovimab on the duration and the severity of COVID-19 clinical symptoms | Time to key clinical symptoms alleviation from symptom onset and sotrovimab administration at baseline, Day 29 after sotrovimab administration and Day of symptoms free (for all 350 patients in the interventional phase and part of the patients in the observational phase). Key clinical symptoms alleviation is defined as the clinical resolution of shortness of breath, fever, and body ache |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the impact of sotrovimab on incidence and duration of time for supplemental oxygen, length of stay (LOS) in the intensive care unit (ICU), and total hospital LOS. | Defined as: Proportion of COVID-19 patients who had ER visits for management of illness, for requirement of supplemental oxygen and/or ICU admission through Day 29 after sotrovimab administration. | 6 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients with mild-to-moderate COVID-19 as confirmed by approved local laboratory tests
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nawal Al Kaabi, MD | Contact | +97124102985 | research@seha.ae |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The National Taskforce for combating COVID-19, Royal Medical Services. | Recruiting | Manama | Bahrain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000711967 | sotrovimab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months |
| To evaluate the impact of sotrovimab in reducing SARS-CoV-2 viral load and in preventing COVID-19 respiratory disease progression. | 6 months |
| To assess the safety of sotrovimab in real-life setting in the UAE and Bahrain | Defined as:
| 6 months |
| To assess the impact of sotrovimab on the strength and duration of the immune response to natural SARS-CoV-2 infection in real-life setting in the UAE and Bahrain. | Defined as: • Change from baseline in mean levels of elevated SARS-CoV-2 functional neutralising antibodies at Day 29, Day 60 and Day 180 after sotrovimab administration in patients, who received their complete or incomplete vaccination course within 3 months prior to COVID-19 symptom onset, these will be presented as proportion of patients with that response. | 6 months |
| Quality of life of patients infused with Sotrovimab | Defined as Change from baseline in health-related quality of life at Day 29 after sotrovimab administration according to the 20-item short form (SF-20) questionnaire (where available / in a selected fraction of patients only in the prospective arm). The questionnaire contains items on physical functioning, role functioning, social functioning, mental health, health perception and pain, the score of all measures is transformed linearly to 0-100 scales, with 0 and 100 assigned to the lowest and highest possible scores, respectively. a high score indicates better health | 6 months |
| To evaluate the clinical impact of sotrovimab in preventing mortality. | Defined as All-cause mortality during 29 days after sotrovimab administration | 6 months |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |